Does finasteride cause decreased libido in women, and how should it be managed?

Finasteride and Decreased Libido in Women

The available evidence does not specifically document decreased libido as a side effect of finasteride in women, though the drug's sexual side effects are well-established in men. The guideline literature focuses on finasteride's efficacy and teratogenicity concerns in women rather than sexual dysfunction 1.

What the Evidence Shows

Sexual Side Effects Profile

The FDA label and clinical trials data for finasteride document decreased libido extensively in men only 2. In male patients:

• Decreased libido occurred in 6.4% (finasteride) vs 3.4% (placebo) in year 1
• This rate decreased to 2.6% in both groups by years 2-4
• The effect was dose-dependent, with combination therapy showing 11.6% incidence

Evidence Gap in Women

The 2019 Androgen Excess and PCOS Committee guideline makes no mention of sexual dysfunction or decreased libido as adverse effects in women treated with finasteride 1. The guideline extensively discusses:

• Efficacy data in postmenopausal women (doses 2.5-5 mg daily)
• Limited data in premenopausal women
• Teratogenic risks requiring strict contraception
• No sexual side effects are documented

This absence is notable given the comprehensive nature of the guideline, which details other antiandrogen side effects (e.g., flutamide's hepatotoxicity, spironolactone's diuretic effects).

Clinical Interpretation

Why This Matters

The mechanism of finasteride (5α-reductase inhibition) theoretically could affect female sexual function by:

• Reducing DHT, which may play a role in female sexual response
• Altering neurosteroid production
• However, no clinical studies have systematically evaluated this in women

Practical Management Approach

If a woman on finasteride reports decreased libido:

1. Assess temporal relationship: Did symptoms begin after starting finasteride?

2. Evaluate alternative causes:

   • Underlying hyperandrogenism itself (which finasteride treats)
   • Concurrent medications (oral contraceptives, antidepressants)
   • Psychosocial factors related to hair loss
   • Hormonal status (pre- vs postmenopausal)

3. Consider alternative antiandrogens if temporal relationship is clear 1:

   • Spironolactone 100-200 mg daily: Better documented in women, though also lacks specific sexual side effect data
   • Requires ≥12 months treatment
   • More effective in women with concurrent hirsutism/acne

4. Optimize first-line therapy:

   • Topical minoxidil 5% should be the primary treatment 1
   • Reserve systemic antiandrogens for severe cases or hyperandrogenism

Critical Caveats

• The absence of evidence is not evidence of absence: Women may experience sexual side effects that haven't been systematically studied
• Most finasteride studies in women excluded premenopausal patients due to teratogenicity concerns, limiting safety data in younger women 1
• The guideline emphasizes that "large unbiased prospective controlled studies are needed" for finasteride in women 1
• Strict contraception is mandatory during treatment and ≥30 days after discontinuation 1

Bottom Line

While finasteride clearly causes decreased libido in men (documented in FDA labeling 2), there is no published evidence documenting this effect in women. If decreased libido occurs temporally with finasteride initiation in a female patient, consider switching to spironolactone or optimizing topical minoxidil monotherapy, as these have better-established safety profiles in women for female pattern hair loss.